Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1135585

	registered interest
	date	28/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Healthy Start Scheme: Yorkshire and the Humber
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many families are in receipt of Healthy Start vouchers in (a) Barnsley Central, (b) Sheffield City Region Mayoral Combined Authority and (c) Yorkshire and the Humber region.
	tabling member constituency	Barnsley Central
	tabling member printed	Dan Jarvis
	uin	270797
	answer	answer is ministerial correction date of answer 08/07/2019 answer text <p>The information is not held in the format requested.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 08/07/2019 14:58:15 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4243 label Biography information for Dan Jarvis

1506291

	registered interest
	date	08/09/2022
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Business: Regulation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he is taking to reduce the regulatory burden on UK businesses.
	tabling member constituency	Hendon
	tabling member printed	Dr Matthew Offord
	uin	49619
	answer	answer is ministerial correction date of answer 22/09/2022 answer text <p>Cutting red tape is a central part of the Government’s growth policy. The Government is carrying out a major cross-government drive to reform, repeal and replace outdated retained EU law. This will aim to cut £1 billion of red tape for UK businesses, ease regulatory burdens and contribute to the Government’s mission to unite and level up the country.</p><p> </p><p>Through a reformed Better Regulation Framework we will foster alternatives to regulation, bear down on costs, and assess the effects of regulation on innovation and competition in order to deliver growth. Regulators will also work collaboratively with businesses to minimise the costs they face.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 49620 question first answered 22/09/2022 08:23:47 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4006 label Biography information for Dr Matthew Offord

1506292

	registered interest
	date	08/09/2022
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Business
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he is taking to ensure that UK businesses benefit from the UK leaving the EU.
	tabling member constituency	Hendon
	tabling member printed	Dr Matthew Offord
	uin	49620
	answer	answer is ministerial correction date of answer 22/09/2022 answer text <p>Cutting red tape is a central part of the Government’s growth policy. The Government is carrying out a major cross-government drive to reform, repeal and replace outdated retained EU law. This will aim to cut £1 billion of red tape for UK businesses, ease regulatory burdens and contribute to the Government’s mission to unite and level up the country.</p><p> </p><p>Through a reformed Better Regulation Framework we will foster alternatives to regulation, bear down on costs, and assess the effects of regulation on innovation and competition in order to deliver growth. Regulators will also work collaboratively with businesses to minimise the costs they face.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 49619 question first answered 22/09/2022 08:23:47 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4006 label Biography information for Dr Matthew Offord

1140957

	registered interest
	date	22/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Metamizole: Side Effects
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment has been made of the side-effects of the drug metamizole.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	280288
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280289 280290 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4036 label Biography information for Luciana Berger

1140958

	registered interest
	date	22/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Metamizole: Spain
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will have discussions with his Spanish counterpart on the effect of dispensing metamizole to (a) UK and (b) Spanish residents in Spain.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	280289
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280288 280290 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4036 label Biography information for Luciana Berger

1140960

	registered interest
	date	22/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Metamizole: Spain
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps the Government is taking to raise awareness of the potential side-effects of the drug metamizole among UK citizens and tourists in Spain.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Luciana Berger
	uin	280290
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280288 280289 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4036 label Biography information for Luciana Berger

1140806

	registered interest
	date	22/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Public Health: Disadvantaged
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of reductions in public health funding on health inequalities.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	280246
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Public health services can have a significant impact in improving the health of the population and reducing unfair differences between marginalised groups of people or communities.</p><p>The Government has made difficult choices to protect public services in the long term. We remain committed to securing five extra years of healthy, independent life by 2035 and reducing the gap between rich and poor with proposals set out in the Prevention Green Paper and a Long Term Plan for the National Health Service with a greater focus on prevention. We want everyone to have the same opportunity to have a long healthy life, whoever they are and whatever their social circumstances.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280247 question first answered 25/07/2019 16:09:54 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4131 label Biography information for Jim Shannon

1140807

	registered interest
	date	22/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Public Health: Disadvantaged
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of reductions in public health funding on the health and wellbeing of the most marginalised people in the UK.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	280247
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Public health services can have a significant impact in improving the health of the population and reducing unfair differences between marginalised groups of people or communities.</p><p>The Government has made difficult choices to protect public services in the long term. We remain committed to securing five extra years of healthy, independent life by 2035 and reducing the gap between rich and poor with proposals set out in the Prevention Green Paper and a Long Term Plan for the National Health Service with a greater focus on prevention. We want everyone to have the same opportunity to have a long healthy life, whoever they are and whatever their social circumstances.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280246 question first answered 25/07/2019 16:09:54 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4131 label Biography information for Jim Shannon

1140523

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mental Health Services: Hospital Beds
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of occasions when there have been mental-health beds available in hospital wards in England in (a) 2018 and (b) 2019.
	tabling member constituency	Chesterfield
	tabling member printed	Toby Perkins
	uin	279409
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Information on mental health bed availability is not collected centrally.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 279410 question first answered 25/07/2019 16:07:48 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	3952 label Biography information for Mr Toby Perkins

1140524

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mental Health Services: Hospital Beds
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of occasions when a patient needed a mental-health bed but none were available in each CCG area in (a) 2018 and (b) 2019.
	tabling member constituency	Chesterfield
	tabling member printed	Toby Perkins
	uin	279410
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Information on mental health bed availability is not collected centrally.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 279409 question first answered 25/07/2019 16:07:48 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	3952 label Biography information for Mr Toby Perkins